Search research articles
Contact Us
Filters
Showing results (31-40 of 218) with videos related to
Page
of 22
Sort By:
Expert Opinion on Pharmacotherapy
|
May 8, 2026
Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors
Iman Al Noumani, Claire Harrison
Current Hematologic Malignancy Reports
|
May 17, 2023
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis
Guadalupe Ferreira Gomes, Claire Harrison
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 30, 2013
The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms
Clodagh Keohane, Ruben Mesa, Claire Harrison
Blood
|
December 25, 2023
How I treat myeloproliferative neoplasms in pregnancy
Susan Robinson, Monica Ragheb, Claire Harrison
Expert Opinion on Drug Safety
|
June 5, 2014
Safety evaluation of ruxolitinib for treating myelofibrosis
Sofia Galli, Donal McLornan, Claire Harrison
Critical Care (London, England)
|
March 30, 2010
New versus old blood - the debate continues
John Laurie, Duncan Wyncoll, Claire Harrison
Haematologica
|
February 2, 2013
JAK inhibitors: beyond spleen and symptoms?
Francisco Cervantes, Ruben Mesa, Claire Harrison
Expert Review of Hematology
|
September 8, 2015
The use of JAK inhibitors for low-risk myelofibrosis
Samah Alimam, Donal McLornan, Claire Harrison
Medical Oncology (Northwood, London, England)
|
September 18, 2007
Letter to editor. Re: "Effect of concomitant use of pentoxifylline (PTX) and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer"
Lucy Jellett, Claire Harrison, Jonathan McAleese
The New England Journal of Medicine
|
October 6, 2017
Clonal Hematopoiesis and Atherosclerosis
Bruno Cassinat, Claire Harrison, Jean-Jacques Kiladjian
Page
of 22
Search research articles
Search
Showing results (31-40 of 218) with videos related to
Sort By:
Page
of 22
Expert Opinion on Pharmacotherapy
|
May 8, 2026
Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors
Iman Al Noumani, Claire Harrison
Current Hematologic Malignancy Reports
|
May 17, 2023
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis
Guadalupe Ferreira Gomes, Claire Harrison
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 30, 2013
The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms
Clodagh Keohane, Ruben Mesa, Claire Harrison
Blood
|
December 25, 2023
How I treat myeloproliferative neoplasms in pregnancy
Susan Robinson, Monica Ragheb, Claire Harrison
Expert Opinion on Drug Safety
|
June 5, 2014
Safety evaluation of ruxolitinib for treating myelofibrosis
Sofia Galli, Donal McLornan, Claire Harrison
Critical Care (London, England)
|
March 30, 2010
New versus old blood - the debate continues
John Laurie, Duncan Wyncoll, Claire Harrison
Haematologica
|
February 2, 2013
JAK inhibitors: beyond spleen and symptoms?
Francisco Cervantes, Ruben Mesa, Claire Harrison
Expert Review of Hematology
|
September 8, 2015
The use of JAK inhibitors for low-risk myelofibrosis
Samah Alimam, Donal McLornan, Claire Harrison
Medical Oncology (Northwood, London, England)
|
September 18, 2007
Letter to editor. Re: "Effect of concomitant use of pentoxifylline (PTX) and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer"
Lucy Jellett, Claire Harrison, Jonathan McAleese
The New England Journal of Medicine
|
October 6, 2017
Clonal Hematopoiesis and Atherosclerosis
Bruno Cassinat, Claire Harrison, Jean-Jacques Kiladjian
Page
of 22